Cancer Research and Treatment

Original Articles

Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis: Jun Ho Ji, Young Saing Kim, Inkeun Park, Soon Il Lee, Rock Bum Kim, Joon Oh Park, Sung Yong Oh, In Gyu Hwang, Joung-Soon Jang, Haa-Na Song, Jung-Hun Kang; Cancer Res Treat. 2018;50(3):791-800. Published online August 23, 2017; DOI: https://doi.org/10.4143/crt.2017.044

Purpose
Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this study was to investigate the survival benefit of chemotherapy over that of BSC in advanced BTC patients.
Materials and Methods
Advanced BTC patientswith a good performance status (Eastern CooperativeOncologyGroup [ECOG] 0-2) were eligible for the study. Data were retrospectively collected from four tertiary cancer centers and analyzed using propensity score matching (PSM). Of the 604 patients enrolled, 206 received BSC and 398 received chemotherapy. PSM analysis was performed using the following variables: age, ECOG status, carcinoembryonic antigen (CEA) level, white blood cell level, albumin level, total bilirubin level, and aspartate aminotransferase level. The sample size of each group was 164 patients after PSM. Median survival was compared between the two groups by using the Kaplan-Meier method, and prognostic factors were investigated using Cox proportional regression analysis.
Results
In post-PSM analysis, the respective median survival for the chemotherapy and BSC groups was dependent on the following prognostic factors: total population, 12.0 months vs. 7.5 months (p=0.001); locally advanced disease, 16.7 months vs. 13.4 months (p=0.490); cancer antigen 19-9 ≤ 100 IU/mL, 12.7 months vs. 10.6 months (p=0.330); and CEA ≤ 3.4 ng/mL, 17.1 months vs. 10.6 months (p=0.052).
Conclusion
Chemotherapy improved overall survival of patients with advanced BTC who had a good performance status. However, this survival benefit was not observed in BTC patients with locally advanced disease or with lower tumor marker. Individualized approach is needed for initiation of palliative chemotherapy in advanced BTC.

Citations

Citations to this article as recorded by

Observational Study of Best Supportive Care With or Without Oral Capecitabine in Patients With Metastatic Gallbladder Carcinoma at a Tertiary Center in India
Abhinav Srivastava, Shagun Misra, Neeraj Rastogi, Vishwas Kapoor, Shaleen Kumar
JCO Global Oncology.2025;[Epub] CrossRef
National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
Faisal Saud Dar, Zaigham Abbas, Irfan Ahmed, Muhammad Atique, Usman Iqbal Aujla, Muhammad Azeemuddin, Zeba Aziz, Abu Bakar Hafeez Bhatti, Tariq Ali Bangash, Amna Subhan Butt, Osama Tariq Butt, Abdul Wahab Dogar, Javed Iqbal Farooqi, Faisal Hanif, Jahanzai
World Journal of Gastroenterology.2024; 30(9): 1018. CrossRef
Treatment patterns and survival in older adults with unresected nonmetastatic biliary tract cancers
Ali Belkouz, Elise de Savornin Lohman, Jyothi R. Thumma, Bas Groot Koerkamp, Philip R. de Reuver, Martijn G.H. van Oijen, Cornelis J.A. Punt, Hari Nathan, Heinz-Josef Klümpen
Journal of Geriatric Oncology.2023; 14(3): 101447. CrossRef
Main causes of death in advanced biliary tract cancer
Kana Kimura‐Seto, Yasushi Kojima, Shiori Komori, Yuya Hisada, Yuki Otake, Yuka Yanai, Akiko Saito, Naoki Akazawa, Yasuo Tanaka, Chizu Yokoi, Mikio Yanase, Junichi Akiyama, Natsuyo Yamamoto, Kazuhiko Yamada
Cancer Medicine.2023; 12(9): 10889. CrossRef
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
Targeted Oncology.2023; 18(6): 837. CrossRef
Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States From 2000 to 2018
Van Nghiem, Sarah Wood, Rekha Ramachandran, Grant Williams, Darryl Outlaw, Ravikumar Paluri, Young-il Kim, Olumide Gbolahan
Cancer Control.2023;[Epub] CrossRef
Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
Carolina Requeijo, Javier Bracchiglione, Nicolás Meza, Roberto Acosta-Dighero, Josefina Salazar, Marilina Santero, Adriana-G Meade, María Jesús Quintana, Gerardo Rodríguez-Grijalva, Anna Selva, Ivan Solà, Gerard Urrútia, Xavier Bonfill Cosp
Clinical Epidemiology.2023; Volume 15: 1069. CrossRef

8,227 View
213 Download
8 Web of Science
7 Crossref

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies: Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang; Cancer Res Treat. 2012;44(4):235-241. Published online December 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.4.235

Abstract PDF PubReader ePub

PURPOSE
Little is known about outcomes in the use of third-line chemotherapy in cases of advanced gastric cancer (AGC). The primary aim of this retrospective study was to evaluate outcomes of docetaxel-based chemotherapy in patients with AGC that progressed after both oxaliplatin-based and irinotecan-based regimens.
MATERIALS AND METHODS
Eligible patients were those with AGC who had previous chemotherapy including fluoropyrimidine and oxaliplatin as well as fluoropyrimidine and irinotecan and who received subsequent docetaxel-based chemotherapy. Thirty-five patients were retrospectively recruited from 5 medical centers in Korea. Patients received either weekly or 3 weekly with docetaxel +/- cisplatin.
RESULTS
Thirty-one out of 35 patients were evaluated for treatment response. A total of 94 cycles of chemotherapy (median, 2; range, 1 to 7) were administered. The overall response rate was 14.3%, and the disease control rate was 45.7%. The median progression-free survival (PFS) was 1.9 months (95% confidence interval [CI], 1.1 to 2.7 months). The median overall survival (OS) was 3.6 months (95% CI, 2.8 to 4.4 months). PFS and OS were significantly prolonged in patients of the Eastern Cooperative Oncology Group, with performance status of 0 or 1 in multivariate analysis (PFS: hazard ratio[HR], 0.411; 95% CI, 0.195 to 0.868; p=0.020 and OS: HR, 0.390; 95% CI, 0.184 to 0.826; p=0.014, respectively). Four of the 35 patients enrolled in the study died due to infection associated with neutropenia.
CONCLUSION
Our findings suggest that salvage docetaxel-based chemotherapy is a feasible treatment option for AGC patients with good performance status (PS), whereas chemotherapy for patients with poor PS (PS< or =2) should be undertaken with caution for those who previously failed oxaliplatin- and irinotecan-based regimens.

Citations

Citations to this article as recorded by

Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
In-Ho Kim, Seung Joo Kang, Wonyoung Choi, An Na Seo, Bang Wool Eom, Beodeul Kang, Bum Jun Kim, Byung-Hoon Min, Chung Hyun Tae, Chang In Choi, Choong-kun Lee, Ho Jung An, Hwa Kyung Byun, Hyeon-Su Im, Hyung-Don Kim, Jang Ho Cho, Kyoungjune Pak, Jae-Joon Kim
Journal of Gastric Cancer.2025; 25(1): 5. CrossRef
Assessment of novel prognostic biomarkers to predict pathological complete response in patients with non-metastatic triple-negative breast cancer using a window of opportunity design
Chitradurga Rajashekhar Akshatha, Dhanapathi Halanaik, Rajesh Nachiappa Ganesh, Nanda Kishore, Prasanth Ganesan, Smita Kayal, Harichandra Kumar, Biswajit Dubashi
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients
Lucrezia Ferrario, Federica Asperti, Giuseppe Aprile, Jacopo Giuliani
International Journal of Environmental Research and Public Health.2023; 20(3): 2107. CrossRef
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
Journal of Gastric Cancer.2023; 23(1): 3. CrossRef
A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines
Sang Soo Eom, Wonyoung Choi, Bang Wool Eom, Sin Hye Park, Soo Jin Kim, Young Il Kim, Hong Man Yoon, Jong Yeul Lee, Chan Gyoo Kim, Hark Kyun Kim, Myeong-Cherl Kook, Il Ju Choi, Young-Woo Kim, Young Iee Park, Keun Won Ryu
Journal of Gastric Cancer.2022; 22(1): 3. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
What is the value of third‐line chemotherapy in advanced gastroesophageal cancer? A 5‐year retrospective analysis at a single center
Justina Yick Ching Lam, Su Pin Choo, David Wai‐Meng Tai, Iain Bee Huat Tan, Chee Kian Tham, Wen Hsin Koo, Simon Yew Kuang Ong, Soo Fan Ang, Clarinda Wei Ling Chua, Dawn Qingqing Chong, Patrick Tze Hern Teo, Christabel Jing Zhi Lee, Samuel Cheng En Ee, Mat
Asia-Pacific Journal of Clinical Oncology.2020; 16(1): 23. CrossRef
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach

Journal of Gastric Cancer.2019; 19(1): 1. CrossRef
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
Giandomenico Roviello, Alberto D’Angelo, Raheleh Roudi, Roberto Petrioli, Enrico Mini
Journal of Oncology.2019; 2019: 1. CrossRef
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
In Sil Choi, Mihong Choi, Ju Hyun Lee, Jee Hyun Kim, Koung Jin Suh, Ji Yun Lee, Beodeul Kang, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
PLOS ONE.2018; 13(6): e0198544. CrossRef
The role of third-line chemotherapy in recurrent or metastatic gastric cancer
Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Seung Soo Sheen
Medicine.2018; 97(39): e12588. CrossRef
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends
P. Edwards, M. Davidson, V. Calamai, D. Cunningham, N. Starling
Cancer Treatment Reviews.2018; 71: 32. CrossRef
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Takashi Nishimura, Satoru Iwasa, Kengo Nagashima, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku
Gastric Cancer.2017; 20(4): 655. CrossRef
Advanced gastric cancer: is there an optimal chemotherapy regimen?
Kalliopi Andrikou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, Fabio Gelsomino, Monica Barbolini, Stefano Cascinu
Expert Review of Quality of Life in Cancer Care.2017; 2(2): 123. CrossRef
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis
Wing-lok Chan, Kwok-keung Yuen, Steven Wai-kwan Siu, Ka-on Lam, Dora Lai-wan Kwong
Critical Reviews in Oncology/Hematology.2017; 116: 68. CrossRef
Third-line chemotherapy in advanced gastric cancer
Yu Zheng, Xu-Qing Zhu, Xiao-Gang Ren
Medicine.2017; 96(24): e6884. CrossRef
Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?
Massimiliano Salati, Katia Di Emidio, Vittoria Tarantino, Stefano Cascinu
ESMO Open.2017; 2(3): e000206. CrossRef
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone,
The Oncologist.2017; 22(12): 1463. CrossRef
Metastatic gastric cancer treatment: Second line and beyond
Marwan Ghosn, Samer Tabchi, Hampig Raphael Kourie, Mustapha Tehfe
World Journal of Gastroenterology.2016; 22(11): 3069. CrossRef
A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)
Yoon-Koo Kang, Baek-Yeol Ryoo, Shinkyo Yoon, Lin Shen, Jooyun Lee, Chenlu Wei, Yu Zhou, Min-Hee Ryu
Cancer Chemotherapy and Pharmacology.2015; 75(2): 309. CrossRef
Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer
BYUNG HA CHO, HYE SOOK HAN, JIHYUN KWON, JOUNG-HO HAN, SOON MAN YOON, DAE HOON KIM, HYO YUNG YUN, KI HYEONG LEE, SEI JIN YOUN, SEUNG TAIK KIM
Oncology Letters.2015; 10(4): 2481. CrossRef
Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
Hugo Ford, Ioannis Gounaris
Therapeutic Advances in Gastroenterology.2015; 8(4): 189. CrossRef
Chemotherapy beyond second-line in advanced gastric cancer
Sung Min Kim
World Journal of Gastroenterology.2015; 21(29): 8811. CrossRef
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study
Yulong Zheng, Weijia Fang, Chenyu Mao, Joing Qian, Peng Zhao, Xiaochen Zhang, Haiping Jiang, Yi Zheng, Nong Xu
Cancer Chemotherapy and Pharmacology.2014; 74(3): 503. CrossRef

62,474 View
93 Download
24 Crossref

A Phase II Study of Leucovorin, 5-FU and Docetaxel Combination Chemotherapy in Patients with Inoperable or Postoperative Relapsed Gastric Cancer: Kwang-Sun Lee, Ha-Yeon Lee, Eun-Kyung Park, Joung-Soon Jang, Sang-Jae Lee; Cancer Res Treat. 2008;40(1):11-15. Published online March 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.1.11

Abstract PDF PubReader ePub

Purpose

To estimate the effect and toxicity of bimonthly low-dose leucovorin (LV) and fluorouracil (5-FU) bolus plus continuous infusion(LV5FU2) with docetaxel combination chemotheraphy in patients with inoperable or postoperative relapsed gastric cancer.

Materials and Methods

Total 27 patients are enrolled in this study. LV 20 mg/m² (bolus), 5FU 400 mg/m² (bolus), 5-FU 600 mg/m² (24-hour continuous infusion) on day 1, 2, 15, and 16, docetaxel 60 mg/m² (1-hour infusion) on day 15 every 4 weeks.

Results

Total of 141 cycles were administered and response rate were 36.8% with 2 complete response (10.5%) and 5 partial response (26.3%) in 19 evaluable patients. The median response duration is 8.1 months (95% CI, 4.0~12.1). The median progression-free survival time is 6.7 months (95% CI, 5.0~8.5) and the median overall survival time is 11.9 months (95% CI, 4.8~19.1). The grade 3-4 toxcity of neutropenia (24.8%) and anemia (11.3%), neutropenic fever (2.8%) is observed. The grade 1 toxcity of injection site reaction is observed all patients and the grade 1-2 toxcity of alopecia is observed 60%.

Conclusions

LV5FU2 with docetaxel combination chemotheraphy is effective and tolerable in patients with inoperable or postoperative relapsed gastric cancer.

Citations

Citations to this article as recorded by

Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial
Jian-Xian Lin, Yi-Hui Tang, Hua-Long Zheng, Kai Ye, Jian-Chun Cai, Li-Sheng Cai, Wei Lin, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Chao-Hui Zheng, Ping Li, Chang-Ming Huang
Nature Communications.2024;[Epub] CrossRef
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
P C Thuss-Patience, A Kretzschmar, Y Dogan, F Rothmann, I Blau, I Schwaner, K Breithaupt, D Bichev, M Grothoff, C Grieser, P Reichardt
British Journal of Cancer.2011; 105(4): 505. CrossRef

9,099 View
60 Download
2 Crossref

A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting: Gyeong-Won Lee, Jung-Hun Kang, Seok-Hyun Kim, Hea Yong Lee, Ho-Cheol Kim, Won-Sup Lee, Jong-Duk Lee, Young-Sil Hwang, Joung-Soon Jang, Jong-Seok Lee; Cancer Res Treat. 2004;36(5):287-292. Published online October 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.287

Abstract PDF PubReader ePub

Purpose

We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment.

Materials and Methods

Between July 2000 and July 2004, 40 patients who had previously received platinum-based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m² intravenous infusion on day 1 and intravenous ifosfamide 3 g/m² with Mesna® uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks.

Results

One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2~6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3~4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3~21.7%). The median time to disease progression was 2.65 months (range: 2.02~3.20 months), and the median survival was 5.24 months (range: 2.99~7.49 months).

Conclusion

Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.

Citations

Citations to this article as recorded by

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy
Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim
Cancer Research and Treatment.2005; 37(6): 339. CrossRef

9,503 View
52 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Search